Cancer

Pembrolizumab Gets First-Line Indication for mCRC

Posted on: Jun 30, 2020   |   Posted by: Master Doctor

Pembrolizumab Gets First-Line Indication for mCRC

WASHINGTON - The FDA approved the PD-1 inhibitor pembrolizumab as initial treatment of metastatic, mismatch repair deficient /microsatellite instability-high colorectal cancer...

Continue reading ...